Bavarian Nordic A/S
Vesterbrogade 149
Copenhagen
DK-1620
Tel: 45-3326-8383
Fax: 45-3326-8380
Website: http://www.bavarian-nordic.com/
Email: pw@bavarian-nordic.dk
210 articles about Bavarian Nordic A/S
-
Nuance Pharma Announces License and Supply Agreement with Bavarian Nordic on the Development and Commercialization of Respiratory Syncytial Virus (RSV) Vaccine for Adults in China and Selected Asian Markets
3/21/2022
Nuance Pharma announced, that it has entered into an exclusive license and supply agreement with Bavarian Nordic on the development and commercialization of MVA-BN® RSV against respiratory syncytial virus in adults in Chinese Mainland, Hong Kong, Macau, Taiwan, South Korea and certain Southeast Asian countries.
-
Bavarian Nordic Announces License and Supply Agreement with Nuance Pharma on the Development and Commercialization of Respiratory Syncytial Virus (RSV) Vaccine for Adults in China and Selected Asian Markets
3/21/2022
Bavarian Nordic A/S announced, that it has entered into an exclusive license and supply agreement with Nuance Pharma, a Shanghai-based specialty pharmaceutical company, on the development and commercialization of MVA-BN® RSV against respiratory syncytial virus in adults in Chinese Mainland, Hong Kong, Macau, Taiwan, South Korea and certain Southeast Asian countries.
-
Bavarian Nordic Reports Additional Positive Phase 2 Results for its COVID-19 Vaccine Candidate Ahead of Phase 3 Trial
2/28/2022
Bavarian Nordic A/S, a fully integrated vaccines company, announced additional positive results from a Phase 2 clinical trial of its non-adjuvanted COVID-19 vaccine candidate, ABNCoV2, which is being developed as a universal booster vaccine.
-
Bavarian Nordic Announces Breakthrough Therapy Designation for its RSV Vaccine Candidate for the Prevention of Respiratory Syncytial Virus in Older Adults
2/14/2022
Bavarian Nordic A/S announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation for the Company's vaccine candidate, MVA-BN RSV, for active immunization for prevention of lower respiratory tract disease caused by respiratory syncytial virus in adults aged 60 years or older.
-
Bavarian Nordic Commits to Initiating Phase 3 Trial of RSV Vaccine Candidate and to Strengthening its Capital Base
12/6/2021
Bavarian Nordic A/S a fully integrated vaccines company, formally announces its commitment to initiate a Phase 3 clinical trial of its RSV vaccine candidate, MVA-BN® RSV.
-
Bavarian Nordic Reports Positive Topline Phase 2 Results for its COVID-19 Vaccine Candidate
12/5/2021
Bavarian Nordic A/S, a fully integrated vaccines company, announced positive topline results from a Phase 2 clinical trial of its COVID-19 vaccine candidate, ABNCoV2.
-
Zabdeno, a two-dose heterologous vaccine, was well-tolerated and induced antibody responses to the Zaire ebolavirus species 21 days after the second dose in 98% of all participants.
-
Bavarian Nordic Reports Positive Results from Human Challenge Trial of its RSV Vaccine Candidate
9/1/2021
Bavarian Nordic A/S announced results from a human challenge trial of the RSV vaccine candidate, MVA-BN® RSV.
-
Bavarian Nordic Receives Funding from the Danish Ministry of Health to Advance the Development of COVID-19 Booster Vaccine
8/23/2021
Bavarian Nordic A/S announced that the Company has entered a funding agreement with the Danish Ministry of Health to further advance the development of ABNCoV2, the Company’s COVID-19 vaccine candidate.
-
Bavarian Nordic Initiates Phase 2 Clinical Trial of COVID-19 Booster Vaccine
8/23/2021
Bavarian Nordic A/S announced the initiation of a Phase 2 clinical trial of its COVID-19 vaccine candidate, ABNCoV2.
-
Bavarian Nordic Reports Initial Results from First-in-Human Trial of COVID-19 Vaccine
8/9/2021
COPENHAGEN, Denmark, August 9, 2021 – Bavarian Nordic A/S reported initial results from the first-in-human trial of ABNCoV2, led by the PREVENT-nCoV consortium.
-
Bavarian Nordic Assists Public Health England in Response to New Cases of Monkeypox
6/11/2021
Bavarian Nordic A/S announced that the Company was recently engaged by Public Health England and the Medicines and Health Products Regulatory Agency to supply its IMVANEX® smallpox vaccine in response to new cases of monkeypox in the UK.
-
Dynavax Announces Agreement with Bavarian Nordic for Commercialization of HEPLISAV B®, a Two Dose Adult Hepatitis B Adjuvanted Vaccine, in Germany
5/27/2021
Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced it has entered into a commercialization agreement with Bavarian Nordic for the marketing and distribution of HEPLISAV B [Hepatitis B Vaccine (Recombinant), Adjuvanted] in Germany
-
Bavarian Nordic Announces the Launch of Distribution and Marketing of RabAvert® in the U.S. Supported by a U.S. Commercial Team
8/5/2020
Bavarian Nordic Announces the Launch of Distribution and Marketing of RabAvert ® in the U.S. Supported by a U.S. Commercial Team MORRISVILLE, N.C.--( BUSINESS WIRE )-- Bavarian Nordic today announced the initiation of full commercial operations in the U.S. only eight months after completing the acquisition of the manufacturing and global rights to Rabipur ® /RabAvert ® (Rabies Vaccine) and Encepur ® (Tick-Borne Encephalitis Vaccine) from GlaxoSmithKline p
-
Recent Advances in Bavarian Nordic’s Cancer Immunotherapy Platform Published in Nature Communications
11/6/2019
A paper discussing recent preclinical advances of Bavarian Nordic’s novel cancer immunotherapy platform was published in the prominent, peer-reviewed, open access journal, Nature Communications.
-
The vaccine is the only approved non-replicating smallpox vaccine in the U.S. and the only approved monkeypox vaccine anywhere in the world, the company said.
-
Bavarian Nordic Announces U.S. FDA Approval of JYNNEOS™ (Smallpox and Monkeypox Vaccine, Live, Non-replicating) for Prevention of Smallpox and Monkeypox Disease in Adults
9/24/2019
Bavarian Nordic A/S announced that the U.S. Food and Drug Administration has approved JYNNEOS™ for prevention of smallpox and monkeypox disease in adults 18 years of age and older determined to be at high risk for smallpox or monkeypox infection.
-
BioSpace Global Roundup, June 20
6/20/2019
Biotech and pharma companies from across Europe and Asia share company and pipeline updates. -
Bavarian Nordic Initiates Phase 3 Trial of Freeze-dried MVA-BN® Smallpox Vaccine
6/19/2019
Bavarian Nordic A/S announced the initiation of a pivotal Phase 3 trial of the freeze-dried formulation of MVA-BN® smallpox vaccine in 1,110 healthy, vaccinia-naïve subjects.
-
Bavarian Nordic Reports Positive Result from ongoing Phase 2 Trial Evaluating BN-Brachyury in Chordoma
6/5/2019
Bavarian Nordic A/S announced that the Data and Safety Monitoring Board confirmed a partial response in one of the first chordoma patients recruited and treated with the combination of BN-Brachyury and radiation treatment at the first evaluation timepoint.